drugset

drugset / Trial / NCT06214143

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

NCT06214143 ↗

Phase 1/2 Recruiting 68 enrolled Shanghai Pharmaceuticals Holding Co., Ltd

NaSingle-groupOpen-labelTreatment

Summary

This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors

Timeline

Start: 2024-01-11
Primary completion: 2026-12-31
Completion: 2026-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	T3011	Other / unclassified	—	Other

Indications